PIRS News Alert Pieris Pharmaceuticals Inc (PIRS) 2.8500 02/15/2015
Post# of 64074
Posted On: 02/15/2015 9:25:53 AM
Pieris Pharmaceuticals Inc (PIRS) 2.8500 $PIRS
Pieris to Present at the 17th Annual BIO CEO & Investor Conference
Marketwire Canada - Tue Feb 03, 8:11AM CST
Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS), a biotechnology company advancing its proprietary AnticalinA® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will be presenting at The 17th Annual BIO CEO & Investor Conference to be held at the Waldorf Astoria in New York City on Monday, February 9 at 5:00 PM (ET).
Pieris Pharmaceuticals, Inc. Completes Private Placement, Raises $13.6M
Marketwired - Tue Dec 23, 3:56PM CST
Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS) (formerly Marika, Inc.), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today the successful completion of its private placement offering as part of its alternative public offering announced on December 18, 2014. Shares of the Company's common stock are quoted on the OTC Market under the symbol "PIRS."
Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million
Marketwired - Thu Dec 18, 10:18AM CST
Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS) (formerly Marika, Inc.), a Nevada corporation, announced today its successful completion of a share exchange transaction with Pieris AG, a German stock corporation pursuant to which Pieris AG became a wholly-owned subsidiary of the Company. The combined entity is named Pieris Pharmaceuticals, Inc. and will focus solely on the business of Pieris AG, a clinical-stage biopharmaceutical company dedicated to the discovery and development of its proprietary Anticalin® class of biotherapeutics. The share exchange transaction was effected on December 17, 2014, and beginning on December 18, 2014, Pieris will trade under the symbol "PIRS" on the OTC Markets.
Pieris to Present at the 17th Annual BIO CEO & Investor Conference
Marketwire Canada - Tue Feb 03, 8:11AM CST
Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS), a biotechnology company advancing its proprietary AnticalinA® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will be presenting at The 17th Annual BIO CEO & Investor Conference to be held at the Waldorf Astoria in New York City on Monday, February 9 at 5:00 PM (ET).
Pieris Pharmaceuticals, Inc. Completes Private Placement, Raises $13.6M
Marketwired - Tue Dec 23, 3:56PM CST
Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS) (formerly Marika, Inc.), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today the successful completion of its private placement offering as part of its alternative public offering announced on December 18, 2014. Shares of the Company's common stock are quoted on the OTC Market under the symbol "PIRS."
Pieris Pharmaceuticals, Inc. Goes Public, Raises $12.2 Million
Marketwired - Thu Dec 18, 10:18AM CST
Pieris Pharmaceuticals, Inc. (OTC PINK: PIRS) (formerly Marika, Inc.), a Nevada corporation, announced today its successful completion of a share exchange transaction with Pieris AG, a German stock corporation pursuant to which Pieris AG became a wholly-owned subsidiary of the Company. The combined entity is named Pieris Pharmaceuticals, Inc. and will focus solely on the business of Pieris AG, a clinical-stage biopharmaceutical company dedicated to the discovery and development of its proprietary Anticalin® class of biotherapeutics. The share exchange transaction was effected on December 17, 2014, and beginning on December 18, 2014, Pieris will trade under the symbol "PIRS" on the OTC Markets.
(0)
(0)Scroll down for more posts ▼